Articles related to CLINICAL TRIALS

Groundbreaking research reveals ketamine’s potential as an effective alternative to ECT in treating treatment-resistant depression, offering new hope to millions.

Uncover the groundbreaking advancements in PNH treatment, from oral therapies to dual inhibition strategies, and their implications for patient outcomes.

The recent phase 3 trial has demonstrated that the combination of the KRAS G12C inhibitor, sotorasib, with the EGFR inhibitor, panitumumab, can lead to longer progression-free survival in patients with chemorefractory metastatic colorectal cancer.

The study’s findings suggest that ibrutinib–venetoclax therapy could potentially revolutionize the treatment of CLL. With a significant reduction in disease progression or death at a median of 43.7 months, this therapy could offer a promising alternative to the standard FCR regimen.

The addition of subcutaneous daratumumab to a standard myeloma regimen has been shown to significantly improve progression-free survival and response rates in transplantation-eligible patients with newly diagnosed multiple myeloma, according to a recent phase 3 clinical trial.

The recent LODESTAR clinical trial has revealed that although the two statins are equally effective in preventing heart attacks, strokes, and death, one has been associated with a higher risk of developing type 2 diabetes and requiring cataract surgery.